Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The partnership will focus on developing potential new vaccines to treat certain selected autoimmune indications, as well as food allergies.

Vaccination 245

Vaccination Vaccine Development Allergies 245

Medical Xpress

APRIL 6, 2023

Black and Hispanic patients with severe allergies are less likely to get a common treatment, allergen immunotherapy, compared to white patients, according to Penn State College of Medicine researchers.

Allergies 77

Allergies Medicine Development Research 77

XTalks

OCTOBER 6, 2022

According to the Asthma and Allergy Foundation of America, about 32 million people in the US have food allergies, which means allergy friendly food brands not only have a large audience base, but are also necessities. Partake Foods has become one of the most popular allergy friendly food brands and it recently secured $11.5

Allergies 90

Allergies Branding Production Packaging 90

pharmaphorum

OCTOBER 10, 2022

For the 32 million individuals in the US with food allergies, more research into symptoms, causes, and treatments has been long sought after, but historically underfunded. per person being spent on food allergy research. Luckily for those with food allergies, the food allergy sector has benefitted from this influx of funding.

Allergies 110

Allergies Marketing Doctors Doctor 110

Trialfacts

OCTOBER 3, 2022

What if a baby is more prone to getting allergies because of poor gut immunity? The kind of bacteria in the human gut during infancy may affect the development of allergic disease later in life. An infant allergy development prevention research study is being done across multiple research sites in the United States and Australia.

Allergies 52

Allergies Development Production Research 52

Trialfacts

OCTOBER 3, 2022

What if a baby is more prone to getting allergies because of poor gut immunity? The kind of bacteria in the human gut during infancy may affect the development of allergic disease later in life. An infant allergy development prevention research study is being done across multiple research sites in the United States and Australia.

Allergies 52

Allergies Development Production Research 52

Pharma Times

MAY 12, 2022

The study is the UK’s most comprehensive allergy test, analysing 295 allergens, including well known potential food allergens

Allergies 101

Allergies Development 101

Medical Xpress

DECEMBER 2, 2022

The presence of food-specific IgA antibodies in the gut does not prevent peanut or egg allergies from developing in children, according to a Northwestern Medicine study published in Science Translational Medicine.

Allergies 81

Allergies Antibody Medicine Development 81

Delveinsight

AUGUST 2, 2021

Peanut allergy (PA) is one of the most common food allergies that affect children in Western nations. Historically, the gold standard of the treatment for Peanut allergy constituted a strategic plan for peanut avoidance coupled with an adrenaline auto-injector (AAI) in case of contingencies.

Allergies 97

Allergies Marketing Development Trials 97

Drug Discovery World

JUNE 26, 2023

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The post Could a monoclonal antibody treat peanut allergy?

Allergies 52

Allergies Antibody In-Vivo In-Vitro 52

BioPharma Reporter

SEPTEMBER 1, 2020

Swiss giant Nestlà is to acquire Aimmune Therapeutics, a biopharmaceutical company developing and commercializing treatments for food allergies. Aimmuneâs Palforzia is the worldâs first approved treatment for peanut allergy.

Allergies 98

Allergies Development 98

BioSpace

AUGUST 4, 2020

emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions. Startup IgGenix, Inc.

Allergies 91

Allergies Development Antibody 91

STAT News

JANUARY 18, 2023

The National Institute of Allergy and Infectious Diseases reported Wednesday that a Phase 3 clinical trial of a vaccine was stopped because the vaccine was ineffective at preventing HIV infection. The vaccine was being developed by Janssen, the vaccine division of Johnson & Johnson. Yet another experimental HIV vaccine has failed.

Clinical Trials 145

Clinical Trials Clinical Trials Vaccination Vaccine 145

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Trialfacts

MARCH 2, 2024

IRB: This study has been reviewed and approved by the Johns Hopkins Medical Center Institutional Review Board About the Study Did you know that nearly 3 percent of infants in the United States develop a food allergy within their first year of life? Let’s safely navigate the challenges of food allergies in the years to come!

Allergies 52

Allergies Research Development 52

Drug Discovery World

OCTOBER 13, 2022

New research has shown that standard cat allergy treatment can be enhanced to make it more effective and faster acting, and the benefits last for a year after treatment ends. The findings of the study, supported by the National Institutes of Health, were published in the Journal of Allergy and Clinical Immunology. .

Allergies 52

Allergies Gene Antibody Trials 52

XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. Related: Red Meat Allergy Test Gets FDA Clearance.

Allergies 98

Allergies Antibody In-Vitro Development 98

BioTech 365

AUGUST 24, 2021

Grass Pollen Allergy Drugs In Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com Grass Pollen Allergy Drugs In Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Grass Pollen Allergy (Immunology) – Drugs In Development, 2021” report has been added (..)

Allergies 40

Allergies Development Drugs 40

Scienmag

NOVEMBER 17, 2020

Credit: Eliot Herman Food allergies are a big problem. suffer from some kind of food allergy. These allergies cost a whopping $25 billion in health care each year. About 7% of children and 2% of adults in the U.S. Then there’s the time lost at school or work.

Allergies 72

Allergies Genetics Development Research 72

pharmaphorum

OCTOBER 27, 2021

Stallergenes Greer has teamed up with Aptar Pharma to develop a digital dimension for its allergen immunotherapy (AIT) products that it hopes will improve the chances of patients completing their treatment. ” The post Allergy specialist Stallergenes taps Aptar for digital delivery appeared first on.

Allergies 63

Allergies Drug Delivery Development Marketing 63

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

Scienmag

APRIL 20, 2021

Babies born by caesarean section to mothers of Asian descent are eight times more likely to develop peanut allergy by age three, study shows Credit: Faculty of Medicine & Dentistry, University of Alberta Researchers have found a causal link between caesarean section birth, low intestinal microbiota and peanut sensitivity in infants, and they report (..)

Allergies 86

Allergies Bacteria Medicine Development 86

Medical Xpress

FEBRUARY 14, 2023

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have removed a major roadblock to better understanding of mpox (formerly, monkeypox).

Scientist 98

Scientist Development Allergies Genetics 98

Bio Pharma Dive

JULY 18, 2022

The food giant will pay French company Enterome about $40 million to join in the development of an inflammatory bowel disease drug as well as other food allergy treatments.

Allergies 254

Allergies Drugs Development 254

pharmaphorum

DECEMBER 10, 2020

Moncef Slaoui, co-head of the US government’s Operation Warp Speed COVID-19 vaccine programme, made the comments after the UK drugs regulator advised those with severe allergies to avoid the vaccine. The post Coronavirus vaccine may have allergy warning in US, says expert appeared first on.

Allergies 101

Allergies Vaccination Vaccine Regulation 101

Delveinsight

DECEMBER 23, 2020

As per the Food Allergy Research & Education, in the US, each year, around 200,000 people require emergency medical care for allergic reactions to food. Food allergy is a specific immune response to certain food items that it considers harmful. The symptoms of food allergy vary from person to person and can also differ over time.

Allergies 52

Allergies Immune Response Production Development 52

BioTech 365

NOVEMBER 23, 2021

ATCC Announces Award from National Institute of Allergy and Infectious Diseases (NIAID) to Develop Research Capabilities in Infectious, Immunologic and Allergic Diseases ATCC Announces Award from National Institute of Allergy and Infectious Diseases (NIAID) to Develop Research Capabilities in Infectious, … Continue reading →

Allergies 52

Allergies Development Research 52

Scienmag

JUNE 27, 2022

million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a low-dose, oral COVID antiviral drug that can be administered at home. . — Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5

Development 94

Development Allergies Research Drugs 94

NY Times

DECEMBER 25, 2020

The patient, who has a severe shellfish allergy, recovered quickly with treatment. Until now, reports of severe reactions had been linked to the Pfizer vaccine.

Vaccination 145

Vaccination Vaccine Doctors Doctor 145

Pharmaceutical Technology

JUNE 28, 2022

grant from the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) for developing a Covid-19 oral antiviral drug. award to researchers at Michigan State University to develop artificial intelligence algorithms that could predict crucial features with the evolution of viruses.

Development 147

Development Bioinformatics Drugs Allergies 147

BioPharma Reporter

MAY 20, 2022

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

Allergies 105

Allergies Drugs Development Drug Delivery 105

The Pharma Data

MARCH 15, 2022

Itchy allergy eyes affect an estimated 40% of Americans 1. Allergan, an AbbVie (NYSE: ABBV) company, today announced that LASTACAFT ® (alcaftadine ophthalmic solution 0.25%) is now available without a prescription for the estimated 40% of Americans 1 who live with ocular allergies. 2 Following the recent U.S.

Allergies 52

Allergies Production Containment Medicine 52

Medical Xpress

MAY 10, 2023

The strongest risk factor for developing asthma is the presence of allergies, but it's unclear why only some individuals with allergies go on to develop asthma.

Allergies 98

Allergies Gene Development 98

pharmaphorum

AUGUST 5, 2020

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. The rationale behind Viaskin Peanut is to expose people with peanut allergy to small, rising amounts of peanut protein – which acts as an allergen – to encourage the immune system to develop tolerance over time.

Allergies 52

Allergies Production Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 4, 2021

4, 2021 — Mothers who drink cow’s milk while breastfeeding may reduce their child’s risk of developing food allergies , a new Swedish study suggests. The findings held after the researchers took into account other factors known to increase allergy risk in children, such as genetics. MONDAY, Jan.

Allergies 52

Allergies Doctors Doctor Dermatology 52

BioTech 365

OCTOBER 28, 2020

DUBLIN–(BUSINESS WIRE)–The “Cat Allergy R&D Pipeline Analysis Report, Q4 2020” report has been added to ResearchAndMarkets.com’s offering.

Allergies 40

Allergies Development Drugs 40

Pharmaceutical Commerce

NOVEMBER 27, 2023

Alladapt Immunotherapeutics said the FDA Fast Track designation highlights the importance of developing a treatment for multiple food allergens.

Allergies 52

Allergies Development 52